CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Prestige Consumer Healthcare Q2 revenue beats on acquisition boost 

By Reuters News


Overview

  • US consumer healthcare firm's Q2 revenue rose 22.7%, beating analyst expectations

  • Adjusted diluted EPS for Q2 increased to $1.13 from $1.07 last year

  • Company cut fiscal 2027 revenue and EPS outlook due to Clear Eyes® supply issues


Outlook

  • Prestige Consumer Healthcare cuts FY27 revenue outlook to $1.28 bln-$1.29 bln

  • Company lowers FY27 adjusted diluted EPS forecast to $4.48-$4.55

  • Company expects Clear Eyes® supply constraints to weigh on second-half revenue


Result Drivers

  • ACQUISITIONS - Revenue growth driven by contributions from Breathe Right and LaCorium acquisitions in both North American and International segments

  • CLEAR EYES DECLINE - Organic revenue fell due to lower Clear Eyes sales and order timing headwinds

  • HYDRALYTE GROWTH - International segment benefited from double-digit sales growth for Hydralyte


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$336.31 mln

$329.13 mln (7 Analysts)

Q2 Net Income

$25.30 mln

Q2 Gross Profit

$172.54 mln

Q2 Operating Expenses

$91.83 mln

Q2 Operating Income

$80.71 mln

Q2 Pretax Profit

$47.45 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc. is $69.50, about 30.4% above its November 4 closing price of $53.28

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth

  • Nov 4 - CVS beats Q3 revenue, profit estimates, outlook raised; to split into two

  • Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.